COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (RITE-USA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03335059
Recruitment Status : Terminated (poor enrollment)
First Posted : November 7, 2017
Last Update Posted : April 15, 2020
Information provided by (Responsible Party):
Medical Enterprises Ltd.

Brief Summary:

This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free duration for complete responders. The study will also explore progression-free survival time, bladder preservation rate, and overall survival time.

The study will address an unmet need to identify a treatment effective in both ablating the disease and providing a prolonged disease-free period for patients. Ideally, the treatment will delay progression to invasive disease, thus preserving the bladder.

Condition or disease Intervention/treatment Phase
Bladder Cancer Bladder Neoplasm Bladder Tumors Cancer of Bladder Cancer of the Bladder Malignant Tumor of Urinary Bladder Neoplasms, Bladder Urinary Bladder Cancer Carcinoma in Situ of Bladder Papillary Carcinoma of Bladder (Diagnosis) BCG-Unresponsive Bladder Cancer Combination Product: Synergo® RITE + MMC Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC
Actual Study Start Date : April 4, 2019
Actual Primary Completion Date : February 26, 2020
Actual Study Completion Date : February 26, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: Synergo® RITE + MMC
Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
Combination Product: Synergo® RITE + MMC
Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
Other Names:
  • radiofrequency hyperthermia with mitomycin C
  • RF hyperthermia with mitomycin C
  • thermochemotherapy
  • chemohyperthermia
  • CHT
  • radio-frequency hyperthermia with mitomycin C

Primary Outcome Measures :
  1. complete response rate (CRR) [ Time Frame: 3 months after the initiation of study therapy ]
    • no CIS
    • no papillary HG tumor
    • no papillary T1 tumor
    • no extra-vesical UC tumor
    • no progression

    a patient will be considered a complete responder only if all the criteria above are met.

    Patients experiencing a new occurrence of a benign tumor or low-grade Ta will be allowed to continue in the study (tumor will be resected); such an occurrence will not constitute an event in the primary analysis.

    Patients with tumors of the ostium and/or upper tract and/or prostatic urethra will be considered to have achieved a complete response in the primary analysis but will be removed from the study.

Secondary Outcome Measures :
  1. disease-free duration of complete response (DCR) [ Time Frame: through study completion, up to 33 months ]
    time of recurrence for complete response patients from the 3-month visit until the time of recurrence or until the last follow-up, whichever occurs sooner.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with current CIS of the bladder, with or without coexisting papillary Ta/T1 NMIBC tumor(s), who experienced an occurrence or recurrence of CIS within 12 months of completion of adequate BCG7 therapy. An adequate BCG regimen shall consist of at least 2 courses of BCG where the first course (induction) must have included at least 5 of 6 weekly treatments and the second course may have included a re-induction (at least 2 of 6 treatments) or maintenance, (at least 2 of 3 treatments) administered on a schedule similar to the SWOG 8507 study regimen.
  2. All clinical, intra-operative and pathological items for the AUA risk stratification must be documented. This includes bladder mapping, according to the instructions specified in the protocol. With regard to BCG and/or other NMIBC treatments documentation must include:

    1. Date of initial treatment,
    2. Date of last treatment,
    3. The number of courses administered and the number of treatments administered in each course.
  3. Patients with concomitant papillary tumor(s) must have undergone a repeat TUR 2-4 weeks prior to the first study treatment:

    1. if the previous TUR was incomplete,
    2. if there was no muscle in the specimen after the initial TUR (except in TaLG tumors),
    3. in all T1,
    4. in all HG tumors ≥ 3cm.
  4. CT-IVU or MRI-IVU or IVU/retrograde confirmation of absence of tumor(s) in the upper tract, kidney and ureters performed within 6 months before the study treatment initiation, in selected cases, as recommended in latest AUA guidelines published prior to screening. If IVU/retrograde protocol is not available or contrast allergy/poor renal function preclude such imaging, then non-contrast CT or MRI of the abdomen/pelvis within the same timeframe will suffice.
  5. Visual inspection to exclude urothelial carcinoma (UC) in the urethra during cystoscopy.
  6. Biopsy of the prostatic urethra, prior to enrollment, to exclude UC of the prostatic urethra, in male patients with:

    1. tumor of trigone,
    2. tumor of bladder neck, or
    3. abnormal prostatic urethra
    4. prior history of prostatic urethral involvement.
  7. All patients must have urine cytology collected from either voided urine or bladder wash within the screening period prior to enrollment. Patients with positive cytology must also have selective cytology from the upper tract and prostatic urethral biopsies collected within the same period. Patients with a localizing positive upper tract cytology are excluded from the study until definitive treatment renders them free of disease visually and/or radiographically and cytologically (nephroureterectomy, distal ureterectomy or upper tract therapy).
  8. Age ≥ 18 yrs.
  9. No evidence of urothelial cancer in either kidneys or ureters.
  10. Pre-treatment hematology and biochemistry values within the limits:

    1. Hemoglobin ≥ 10 g/dl (g/100 ml)
    2. Platelets ≥ 150 x 10^9/L (x 10^3/mm^3)
    3. WBC ≥ 3.0 x 10^9/L (x 10^3/mm^3)
    4. ANC ≥ 1.5 x 10^9/L (x 10^3/mm^3)
    5. Serum creatinine < 2 mg/dl
    6. SGOT < 1.5 x ULN
    7. SGPT < 1.5 x ULN
    8. Alkaline phosphatase < 1.5 x ULN
  11. Negative pregnancy test for women of childbearing potential.
  12. A life expectancy at least of the duration of the study.
  13. Signed informed consent.

Exclusion Criteria:

  1. Non-UC tumor of the urinary tract.
  2. Upper tract and/or intramural tumors (e.g., in ostium).
  3. Positive selective cytology from the upper tract.
  4. History of stage > T1 UC.
  5. Papillary tumors > T1 in repeat TUR.
  6. Known or suspected reduced bladder capacity. Patients will have an ultrasonic estimation of maximum bladder capacity or void spontaneously the maximum they can retain in their bladder, and this will be used to determine urine volume. A minimum volume of 250 ml is required.
  7. Patients with severe bladder outlet obstruction not adequately controlled with medication (AUA symptom score ≥ 20).
  8. Bleeding disorder.
  9. Gross hematuria within the past 2 weeks before treatment start.
  10. Lactating women.
  11. Women of childbearing potential unwilling or unable to use adequate contraception if sexually active.
  12. More than low-dose methotrexate (>17.5 mg once a week).
  13. Other malignancy within the past 5 years, except: non melanomatous skin cancer cured by excision, surgically treated carcinoma in situ of the cervix or ductal CIS (DCIS)/lobular CIS (LCIS) of the breast or stable prostate cancer (under active surveillance or hormone control) with a life expectancy of more than 5 years.
  14. Any known allergy (e.g., to MMC) or adverse event that would prevent a prospective study participant from receiving the study treatment.
  15. Known untreated urethral strictural disease or bladder neck contracture or any other condition that may prevent catheterization with a 21F catheter. Patients may undergo dilation or urethral incision before entering the study.
  16. Bladder diverticulum with diameter > 1cm, as determined by CT or cystography
  17. UTI at any time within 3 weeks before study treatment initiation.
  18. Significant urinary incontinence (spontaneous, requiring use of > 1 pad/day (PPD)).
  19. History of pelvic irradiation.
  20. Patients with electronic devices implanted in abdominal cavity.
  21. Participation in another study, unless discussed with and approved by the Sponsor or Sponsor's authorized representative.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03335059

Layout table for location information
United States, Maryland
Chesapeake Urology Research Associates
Hanover, Maryland, United States, 21076
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Medical Enterprises Ltd.
Layout table for investigator information
Principal Investigator: Michael A O'Donnell, MD University of Iowa
Layout table for additonal information
Responsible Party: Medical Enterprises Ltd. Identifier: NCT03335059    
Other Study ID Numbers: RITE-1
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: April 15, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medical Enterprises Ltd.:
Bacillus Calmette-Guérin
radio frequency
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Carcinoma in Situ
Carcinoma, Papillary
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Neoplasms, Squamous Cell
Antibiotics, Antineoplastic
Antineoplastic Agents
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors